p-AAV-sh[SNCA] Citations (3)

Originally described in: shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model.
Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT, Burton EA J Clin Invest. 2015 Jul 1;125(7):2721-35. doi: 10.1172/JCI64502. Epub 2015 Jun 15. PubMed Journal

---

Articles Citing p-AAV-sh[SNCA]

Articles
Long-term RNAi knockdown of alpha-synuclein in the adult rat substantia nigra without neurodegeneration. Zharikov A, Bai Q, De Miranda BR, Van Laar A, Greenamyre JT, Burton EA. Neurobiol Dis. 2019 May;125:146-153. doi: 10.1016/j.nbd.2019.01.004. Epub 2019 Jan 15. PubMed
alpha-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo. Van Laar VS, Chen J, Zharikov AD, Bai Q, Di Maio R, Dukes AA, Hastings TG, Watkins SC, Greenamyre JT, St Croix CM, Burton EA. Redox Biol. 2020 Oct;37:101695. doi: 10.1016/j.redox.2020.101695. Epub 2020 Aug 22. PubMed
VAP spatially stabilizes dendritic mitochondria to locally support synaptic plasticity. Bapat O, Purimetla T, Kruessel S, Shah M, Fan R, Thum C, Rupprecht F, Langer JD, Rangaraju V. Nat Commun. 2024 Jan 4;15(1):205. doi: 10.1038/s41467-023-44233-8. PubMed

If you have published an article using this material, please email us at to have your article added to this page.